Prelude Capital Management’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Prelude Capital Management’s Portfolio CMTA Stock Details CMTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-36,930	Closed	-$964K	–	2374
2019 Q1	$964K	Buy	36,930 +35,397	+2,309%	+$661K	0.05%	339
2018 Q4	$18K	Sell	1,533 -721	-32%	-$8.97K	﹤0.01%	1266
2018 Q3	$25K	Sell	2,254 -911	-29%	-$9.59K	﹤0.01%	1274
2018 Q2	$42K	Sell	3,165 -552	-15%	-$8.94K	﹤0.01%	1173
2018 Q1	$56K	Buy	3,717 +334	+10%	+$5.43K	﹤0.01%	1038
2017 Q4	$64K	Buy	3,383 +215	+7%	+$3.6K	0.01%	888
2017 Q3	$54K	Buy	+3,168	New	+$51.8K	﹤0.01%	1077

Prelude Capital Management's CMTA Position: Q2 2019 in Review

Prelude Capital Management sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2019, closing a stake of 36,930 shares — an estimated $964K sold.

Prelude Capital Management first reported a position in CMTA in Q3 2017 and held it in 7 quarters. The position peaked at $964K in Q1 2019. 0 funds tracked by Wall St. Rank hold CMTA as of Q2 2019.

Prelude Capital Management reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Prelude Capital Management sold 36,930 Clementia Pharmaceuticals Inc. shares in Q2 2019, an estimated $964K.
Prelude Capital Management first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 7 quarters.
Prelude Capital Management's Clementia Pharmaceuticals Inc. position peaked at $964K in Q1 2019.
0 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2019.

Based on Prelude Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.